Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708759 | 0.81 | KMT2A (0.52) | CA12CA1CA2CA9CA14 | |
| SCHEMBL17433499 | 0.79 | SRD5A2 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL11554501 | 0.76 | ALDH1A1 (0.32) | KMT2A | |
| SCHEMBL7588248 | 0.74 | ALDH1A1 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL109451 | 0.74 | CA1 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1019092 | 0.73 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL16617577 | 0.73 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7385067 | 0.73 | CA1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL8024736 | 0.72 | CA1 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1919683 | 0.72 | CA1 (0.50) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964661-B1 | METALLOCENE COMPOUNDS AND LABELED MOLECULES COMPRISING THE SAME FOR IN VIVO IMAGING | APTENIA S R L (IT) | 2018-01-10 | — | — | EP | disclosed |
| US-9399077-B2 | Metallocene compounds and labeled molecules comprising the same for in vivo imaging | APTENIA S.R.L. (IT) | 2016-07-26 | — | — | US | disclosed |
| US-9399077-B2 | Metallocene compounds and labeled molecules comprising the same for in vivo imaging | APTENIA S.R.L. (IT) | 2016-07-26 | — | — | US | disclosed |
| US-9399077-B2 | Metallocene compounds and labeled molecules comprising the same for in vivo imaging | APTENIA S.R.L. (IT) | 2016-07-26 | — | — | US | disclosed |
| US-20160008495-A1 | Metallocene Compounds and Labeled Molecules Comprising the Same for In Vivo Imaging | APTENIA S.R.L. (IT) | 2016-01-14 | — | — | US | disclosed |
| US-20160008495-A1 | Metallocene Compounds and Labeled Molecules Comprising the Same for In Vivo Imaging | APTENIA S.R.L. (IT) | 2016-01-14 | — | — | US | disclosed |
| US-20160008495-A1 | Metallocene Compounds and Labeled Molecules Comprising the Same for In Vivo Imaging | APTENIA S.R.L. (IT) | 2016-01-14 | — | — | US | disclosed |
| EP-2964661-A1 | METALLOCENE COMPOUNDS AND LABELED MOLECULES COMPRISING THE SAME FOR IN VIVO IMAGING | Aptenia S.R.L. (IT) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014135590-A1 | METALLOCENE COMPOUNDS AND LABELED MOLECULES COMPRISING THE SAME FOR IN VIVO IMAGING | APTENIA S.R.L. (IT) | 2014-09-12 | — | — | WO | disclosed |
| EP-2774930-A1 | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. | Aptenia S.R.L. (IT) | 2014-09-10 | — | — | EP | disclosed |
| EP-2774930-A1 | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. | Aptenia S.R.L. (IT) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008495-A1 | Metallocene Compounds and Labeled Molecules Comprising the Same for In Vivo Imaging | MEN1, MPI, TFRC | CA12 124/4885CA1 159/4885CA2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.